Drug intelligence / Profile preview

exenatide

Development stage: Approved
Lead developer: Bristol Myers Squibb
Modality: Peptides
Administration: Subcutaneous

Overview

Exenatide is a glucagon-like peptide-1 (GLP-1) agonist used in the management of type 2 diabetes mellitus. It works by activating the GLP-1 receptor to increase insulin secretion, decrease glucagon secretion, and slow gastric emptying to improve glycemic control. Exenatide is available in both immediate-release (Byetta) and extended-release (Bydureon, Bydureon BCise) formulations. The FDA approved exenatide on April 28, 2005. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021, while Bydureon BCise, an auto-injector extended-release formulation, remains available.

Brand names: ByettaBydureonBydureon BCise
Other names: Exendin-4Exendin4Exendin 4Synthetic exendin-4

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on exenatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on exenatide.

Explore the full profile